3-(3-氯苯基)-5-异恶唑甲醛 | 869496-60-6

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3-氯苯基)-5-异恶唑甲醛
• 英文名称: 3-(3-chlorophenyl)isoxazole-5-carbaldehyde
• 英文别名: 3-(3-chlorophenyl)-1,2-oxazole-5-carbaldehyde
• CAS: 869496-60-6
• 化学式: C₁₀H₆ClNO₂
• mdl: MFCD06738502
• 分子量: 207.616
• InChiKey: TZCHLLPQCIJQJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-phenyl-N-(4-piperidinylmethyl)isoxazolo[4,5-d]pyridazin-4-amine hydrochloride 、 3-(3-氯苯基)-5-异恶唑甲醛 生成 N-[(1-{[3-(3-chlorophenyl)-5-isoxazolyl]methyl}-4-piperidinyl)methyl]-3-phenylisoxazolo[4,5-d]pyridazin-4-amine
  参考文献：
  名称：

  Piperidine-containing compounds and use thereof

  摘要：

  本发明提供了一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物(I)的有效量：其中所有符号的含义均如规范中所定义；其盐、N-氧化物、溶剂化物或前药。化合物(I-1)的新型化合物：其中所有符号的含义均如规范中所定义；其盐、N-氧化物、溶剂化物或前药具有抗糖尿病和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。

  公开号：

  US08809538B2
• 作为产物：
  描述：

  3-chlorobenzaldehyde oxime 在 吡啶 、 N-氯代丁二酰亚胺 、 silica gel 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 3-(3-氯苯基)-5-异恶唑甲醛
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Focused Isoxazolylpiperidinylpiperazine Library for Dopamine D₃and D₄Receptor Antagonists

  摘要：

  DOI：

  10.5012/bkcs.2011.32.7.2449

文献信息

• [EN] PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DE LA PIPÉRIDINE ET LEURS UTILISATIONS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010080864A1

  公开（公告）日：2010-07-15

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物的有效量，其化学式为(I)，其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药。以及化学式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药具有抗糖尿病作用和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。
• Tunable and Cooperative Catalysis for Enantioselective Pictet‐Spengler Reaction with Varied Nitrogen‐Containing Heterocyclic Carboxaldehydes
  作者：Yuk‐Cheung Chan、Marcus H. Sak、Scott A. Frank、Scott J. Miller

  DOI：10.1002/anie.202109694

  日期：2021.11.8

  We utilize diverse N-heterocyclic carboxaldehyde and regioisomers in Pictet-Spengler reaction. Compatibility was enabled by fine tuning the achiral carboxylic acid co-catalyst in the presence of chiral peptidic squaramide. Synthetic utility was demonstrated by stereoselective synthesis of pyridine-containing analogues of medicinally related molecules, including U.S. FDA approved drug Tadalafil.

  我们在 Pictet-Spengler 反应中利用多种N-杂环甲醛和区域异构体。通过在手性肽方酰胺存在下微调非手性羧酸助催化剂来实现兼容性。通过立体选择性合成医学相关分子的含吡啶类似物（包括美国 FDA 批准的药物他达拉非）证明了合成效用。
• Phenylisoxazole-3/5-Carbaldehyde Isonicotinylhydrazone Derivatives: Synthesis, Characterization, and Antitubercular Activity
  作者：Fernando Carrasco、Wilfredo Hernández、Oscar Chupayo、Patricia Sheen、Mirko Zimic、Jorge Coronel、Celedonio M. Álvarez、Sergio Ferrero、Sandra Oramas-Royo、Evgenia Spodine、Jesus M. Rodilla、Juan Z. Dávalos

  DOI：10.1155/2021/6014093

  日期：2021.10.31

  Eight new phenylisoxazole isoniazid derivatives, 3-(2′-fluorophenyl)isoxazole-5-carbaldehyde isonicotinylhydrazone (1), 3-(2′-methoxyphenyl)isoxazole-5-carbaldehyde isonicotinylhydrazone (2), 3-(2′-chlorophenyl)isoxazole-5-carbaldehyde isonicotinylhydrazone (3), 3-(3′-clorophenyl)isoxazole-5-carbaldehyde isonicotinylhydrazone (4), 3-(4′-bromophenyl)isoxazole-5-carbaldehyde isonicotinylhydrazone (5), 5-(4′-methoxiphenyl)isoxazole-3-carbaldehyde isonicotinylhydrazone (6), 5-(4′-methylphenyl)isoxazole-3-carbaldehyde isonicotinylhydrazone (7), and 5-(4′-clorophenyl)isoxazole-3-carbaldehyde isonicotinylhydrazone (8), have been synthesized and characterized by FT-IR, 1H-NMR, 13C-NMR, and mass spectral data. The 2D NMR (1H-1H NOESY) analysis of 1 and 2 confirmed that these compounds in acetone-d6 are in the trans(E) isomeric form. This evidence is supported by computational calculations which were performed for compounds 1–8, using DFT/B3LYP level with the 6-311++G(d,p) basis set. The in vitro antituberculous activity of all the synthesized compounds was determined against the Mycobacterium tuberculosis standard strains: sensitive H37Rv (ATCC-27294) and resistant TB DM97. All the compounds exhibited moderate bioactivity (MIC = 0.34–0.41 μM) with respect to the isoniazid drug (MIC = 0.91 μM) against the H37Rv sensitive strain. Compounds 6 (X = 4′-OCH3) and 7 (X = 4′-CH3) with MIC values of 12.41 and 13.06 μM, respectively, were about two times more cytotoxic, compared with isoniazid, against the resistant strain TB DM97.

  八种新的苯并异噁唑异烟酰肼衍生物，分别为3-(2'-氟苯基)异噁唑-5-甲醛异烟酰肼酰肼(1)、3-(2'-甲氧基苯基)异噁唑-5-甲醛异烟酰肼酰肼(2)、3-(2'-氯苯基)异噁唑-5-甲醛异烟酰肼酰肼(3)、3-(3'-氯苯基)异噁唑-5-甲醛异烟酰肼酰肼(4)、3-(4'-溴苯基)异噁唑-5-甲醛异烟酰肼酰肼(5)、5-(4'-甲氧基苯基)异噁唑-3-甲醛异烟酰肼酰肼(6)、5-(4'-甲基苯基)异噁唑-3-甲醛异烟酰肼酰肼(7)和5-(4'-氯苯基)异噁唑-3-甲醛异烟酰肼酰肼(8)，已经通过FT-IR、1H-NMR、13C-NMR和质谱数据进行了合成和表征。1和2的2D NMR (1H-1H NOESY)分析证实这些化合物在丙酮-d6中处于反式(E)异构形式。这一证据得到了化合物1-8的计算计算的支持，使用DFT/B3LYP水平和6-311++G(d,p)基组进行了计算。所有合成化合物的体外抗结核活性被测定，对标准菌株分别为敏感的H37Rv (ATCC-27294)和耐药的TB DM97。所有化合物对敏感菌株H37Rv表现出中等的生物活性(MIC = 0.34-0.41 μM)，相对于异烟肼药物(MIC = 0.91 μM)。化合物6 (X = 4'-OCH3)和7 (X = 4'-CH3)的MIC值分别为12.41和13.06 μM，比异烟肼对耐药菌株TB DM97的细胞毒性高出两倍。
• PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF
  申请人：Rodriguez Martha E.

  公开号：US20110275608A1

  公开（公告）日：2011-11-10

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物投与公式(I)化合物的有效量：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药。公式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药具有抗糖尿病和神经保护作用。因此，公式(I)和公式(I-1)的化合物在预防和/或治疗代谢性疾病（如糖尿病）、脑血管疾病（如中风）等方面有用。
• MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS
  申请人：Ashraf Muhammad

  公开号：US20180273906A1

  公开（公告）日：2018-09-27

  Provided herein are stem cell and exosome compositions having therapeutic utility to treat a variety of diseases and disorders, e.g., cardiovascular disease, Duchenne muscular dystrophy, and fibrotic disease.